Skip to main content
Retour
AAPG logo

Ascentage Pharma Group International

Qualité des données : 100%
AAPG
NASDAQ Healthcare Biotechnology
22,32 €
0,00 € (0,00%)
Cap. Boursière : 2,07B
Fourchette du Jour
21,36 € 22,32 €
Fourchette 52 Semaines
17,56 € 48,45 €
Volume
1 129
Moyenne 50J / 200J
24,69 € / 33,17 €
Clôture Précédente
22,32 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -5,1 0,3
P/B 7,9 2,9
ROE % -249,8 3,7
Net Margin % -41,3 3,8
Rev Growth 5Y % 197,9 10,0
D/E 6,3 0,2

Objectif de Cours des Analystes

Hold
48,00 € +115.1%
Low: 45,00 € High: 51,00 €
BPA Prévisionnel
-7,50 €
CA Est.
1 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2029 -8,88 €
-16,59 € – -3,03 €
2,4 B 1
FY2028 -10,81 €
-20,19 € – -3,69 €
1,5 B 1
FY2027 -7,17 €
-13,39 € – -2,45 €
1,2 B 1

Points Clés

Revenue grew 197,91% annually over 5 years — strong growth
Debt/Equity of 6,32 — high leverage
Negative free cash flow of -135,65M
PEG of 0,26 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 143,86%
Capital efficient — spends only 2,48% of revenue on capex

Croissance

Revenue Growth (5Y)
197,91%
Revenue (1Y)341,77%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-249,80%
ROIC-14,35%
Net Margin-41,34%
Op. Margin-37,70%

Sécurité

Debt / Equity
6,32
Current Ratio1,26
Interest Coverage-5,74

Valorisation

P/E Ratio
-5,12
P/B Ratio7,85
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 341,77% Revenue Growth (3Y) 116,25%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 197,91% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 980,65M Net Income (TTM) -405,43M
ROE -249,80% ROA -15,49%
Gross Margin 97,03% Operating Margin -37,70%
Net Margin -41,34% Free Cash Flow (TTM) -135,65M
ROIC -14,35% FCF Growth (3Y) N/A
Safety
Debt / Equity 6,32 Current Ratio 1,26
Interest Coverage -5,74 Dividend Yield 0,00%
Valuation
P/E Ratio -5,12 P/B Ratio 7,85
P/S Ratio 2,12 PEG Ratio 0,26
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 2,07B Enterprise Value 2,51B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 980,65M 221,98M 209,71M 27,91M 12,45M
Net Income -405,43M -925,64M -882,92M -782,42M -677,61M
EPS (Diluted) -5,36 -52,48 -53,60 -49,12 -50,24
Gross Profit 951,57M 191,44M 187,71M 24,58M 10,48M
Operating Income -369,73M -872,64M -849,81M -869,84M -663,94M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 2,62B 2,50B 2,83B 2,94B 1,73B
Total Liabilities 2,34B 2,43B 2,42B 1,71B 884,42M
Shareholders' Equity 264,19M 60,42M 408,66M 1,23B 846,62M
Total Debt 1,67B 1,80B 1,79B 1,08B 529,70M
Cash & Equivalents 1,24B 1,07B 1,48B 1,71B 1,02B
Current Assets 1,47B 1,34B 1,64B 1,89B 1,08B
Current Liabilities 1,17B 934,17M 881,15M 361,11M 276,15M